AstraZeneca plc (AZN)
| Market Cap | 154.86B |
| Revenue (ttm) | 27.58B |
| Net Income (ttm) | 3.96B |
| Shares Out | 2.63B |
| EPS (ttm) | 1.52 |
| PE Ratio | 38.54 |
| Forward PE | 23.53 |
| Dividend | $2.80 |
| Dividend Yield | 4.79% |
| Trading Day | June 16 |
| Last Price | $58.41 |
| Previous Close | $58.84 |
| Change ($) | -0.43 |
| Change (%) | -0.73% |
| Day's Open | 58.86 |
| Day's Range | 58.28 - 59.34 |
| Day's Volume | 6,964,685 |
| 52-Week Range | 46.48 - 63.20 |
AstraZeneca's (AZN) antibody cocktail, AZD7442 fails to prevent people who were already infected from developing symptomatic COVID-19. However, it showed some efficacy in people who were not infected.
AstraZeneca Covid Antibody Cocktail Only 33% Effective
Jun.15 -- AstraZeneca Plc's antibody cocktail was only 33% effective at preventing symptomatic Covid-19 in people who had been exposed to the virus, failing a study that was key to the drugmaker's pande...
AstraZeneca plc (LON:AZN) released its ‘Storm Chaser' study results on Tuesday that at first glance appear disappointing but beyond the headline takeaway, there were some positives. The trial assessed b...
AstraZeneca Plc (NASDAQ: AZN) reported data from the STORM CHASER Phase 3 trial showing that its long-acting antibody (LAAB) combination AZD7442 did not meet the primary endpoint of post-exposure preven...
The monoclonal antibody treatment reduced the risk of developing symptomatic Covid-19 by a statistically insignificant 33% among unvaccinated adults.
The PRAC of the European Medicines Agency (EMA) has advised against giving AstraZeneca's (AZN) Vaxzevria COVID-19 vaccine to people with a history of capillary leak syndrome, a rare blood disorder.
BOSTON, June 8, 2021 /PRNewswire/ -- PathAI, a global leader of AI-powered technology applied to pathology, today announced that new data highlighting a quality control tool for HER2 testing in digital ...
NetScientific PLC's (LON:NSCI), up 235 at 92p, was the top riser after striking a licensing deal with AstraZeneca PLC (LON:AZN). Its ProAxsis subsidiary is to work with AstraZeneca over the validation a...
NetScientific PLC's (LON:NSCI) ProAxsis subsidiary has struck a licensing deal with AstraZeneca PLC (LON:AZN) over the validation and global commercialisation of an assay associated with coronavirus vac...
Astrazeneca (AZN) closed at $56.80 in the latest trading session, marking a +0.98% move from the prior day.
AstraZeneca Plc's (NASDAQ: AZN) has announced updated results from the PACIFIC Phase 3 trial of Imfinzi (durvalumab), showing survival benefit at five years in patients with unresectable Stage III non-s...
AstraZeneca Plc (NASDAQ: AZN) and Merck & Co Inc (NYSE: MRK) have announced the first presentation of data from the Phase 3 OlympiA trial evaluating Lynparza (olaparib) in a subset of early breast cance...
AstraZeneca PLC (LON:AZN) announced it has appointed Aradhana Sarin as an executive director and chief financial officer, effective from 1 August. The appointment is conditional on the success of the US...
Drugmaker AstraZeneca Plc said on Friday it had appointed Alexion's Aradhana Sarin as its new chief financial officer to succeed Marc Dunoyer who would be taking up a new role within the company.
AstraZeneca Plc (NASDAQ: AZN) is in talks with the U.S. government to shift production of its COVID-19 vaccine from a troubled Emergent BioSolutions Inc's (NYSE: EBS) Baltimore plant to a factory owned ...
The party is apparently “On” as far as the developed world's sense of “reopening” is concerned. But the global truth is far removed from this celebration, as less than 20% of the world's population have...
Privately-held Proteros biostructures GmbH has signed an agreement with AstraZeneca Plc (NASDAQ: AZN) to jointly discover and develop novel small molecules for the potential treatment of various types o...
AstraZeneca Plc (NASDAQ: AZN) has announced a new posthoc analysis of pooled data from the TULIP Phase 3 clinical trials evaluating anifrolumab in patients with moderate to severe systemic lupus erythem...
MUNICH--(BUSINESS WIRE)--Proteros biostructures GmbH (“Proteros”) today announced that it has signed an agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) to jointly discover and develop novel small molec...
EU antitrust regulators will decide by July 5 whether to clear Anglo-Swedish drugmaker AstraZeneca's $39 billion bid for U.S.-based Alexion, a European Commission filing showed on Tuesday.
These pharmaceutical companies might make great long-term additions to your portfolio.
AstraZeneca Plc's (NASDAQ: AZN) top-selling Tagrisso drug has been approved for use in the European Union to treat patients with a type of early-stage lung cancer. The European Commission has approved t...
Fast-growing AstraZeneca might make an interesting addition to your portfolio.
Several of these vaccine makers face challenges.
AstraZeneca PLC (LON:AZN) said Tagrisso has been approved in the EU for the adjuvant treatment of adult patients with a type of early-stage lung cancer. It targets epidermal growth factor receptor-mutat...
After the almighty ding-dong over executive pay at AstraZeneca PLC (LON:AZN) earlier this month, two more high-profile companies are in the firing line over their executive pay schemes. Legal & General ...
German scientists at Goethe University have claimed to know why some COVID-19 vaccines can cause blood clots. AstraZeneca PLC (LON:AZN) and Johnson & Johnson (NYSE:JNJ) have both developed DNA-based for...
AstraZeneca PLC (LON:AZN) announced it has priced €800mln (£691mln) of fixed-rate notes related to the proposed acquisition of Alexion Pharmaceuticals, Inc. They have a coupon of 0.375% maturing in 2029...
The European Union took on AstraZeneca Plc (NASDAQ: AZN) in a Brussels court and accused it of diverting doses promised to the bloc to other nations. EU's lawyer, Rafael Jafferali, asked the court to fo...
Japan's Nipro Corporation has signed an agreement to supply AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine in Japan, reports Reuters. Nipro said that the contract was for filling the shot into vials a...
AstraZeneca PLC's (LON:AZN) proposed US$39bn (£27.5bn) acquisition of Alexion Pharmaceuticals, Inc. is now under investigation by the Competition and Markets Authority (CMA).
The U.K. competition regulator is mulling over AstraZeneca Plc's (NASDAQ: AZN) $39 billion takeover taker of Alexion Pharmaceuticals Inc (NASDAQ: ALXN) over competition concern. The U.K.'s Competition a...
AstraZeneca PLC's (LON:AZN) proposed US$39bn (£27.5bn) acquisition of Alexion Pharmaceuticals, Inc. is now under investigation by the Competition and Markets Authority (CMA).
Silence Therapeutics PLC (LON:SLN, NASDAQ:SLN) said it has received the final US$40mln from a US$80mln cash and equity investment from AstraZeneca, adding that it expects to be working on up to five tar...
Britain's competition regulator said on Tuesday it was probing if AstraZeneca's $39 billion takeover of U.S. drugmaker Alexion could reduce competition for products and services in the country or elsewh...
AstraZeneca's (AZN) COVID-19 vaccine Vaxzevria gets an approval for emergency use in Japan for active immunization of individuals aged 18 years and older.
In this week's coronavirus (COVID-19) vaccine news, the UK has reached the 60mln milestone of administered doses. That includes 22mln people having received both shots required to complete the immunisa...
Along with the approval of Moderna's COVID-19 vaccine, Japan's regulatory authority has also approved AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine, Vaxzevria for adults. According to Japan's public ...
Japan has approved the COVID-19 vaccines produced by Moderna Inc (NASDAQ:MRNA) and by AstraZeneca PLC (LON:AZN) in conjunction Oxford University, for people aged over 18. Japan has so far only vaccinate...
AstraZeneca PLC (LON:AZN) announced that the COVID-19 vaccine developed with Oxford University has been granted special approval for emergency use in Japan in people aged over 18. The jab, now called Va...
AstraZeneca PLC's (LON;AZN) Covid-19 vaccine gives between 85-90% effectiveness after two shots, Public Health England said today after analysing data from those inoculated so far. That puts the Astra/O...
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca will present new data underscoring its ambition to redefine cancer care at the American Society of Clinical Oncology (ASCO) Annual Meeting, June 4 to 8, 20...
AstraZeneca Plc (NASDAQ: AZN) has announced results from a new integrated analysis, including data from the MELTEMI Phase 3 open-label extension trial, evaluating Fasenra (benralizumab) in adult patient...
AstraZeneca PLC (NASDAQ:AZN) is in the spotlight today, after the Financial Times reported that the company's Covid-19 vaccine works well as a third booster shot, according to a study by Oxford Universi...
Oxford University and AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine works well as a third booster shot, according to a study, the Financial Times reported citing people familiar with the matter. A th...
Oxford BioMedica Plc (OTC: OXBDF) has raised its forecast for cumulative revenues from AstraZeneca Plc (NASDAQ: AZN) by the end of 2021 to more than £100 million from £50 million pounds earlier. The com...
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of domest...
About AZN
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbico... [Read more...]
| Industry Drug Manufacturers-General | IPO Date May 12, 1993 |
| CEO Pascal Soriot | Employees 76,100 |
| Stock Exchange NASDAQ | Ticker Symbol AZN |
Financial Performance
In 2020, AstraZeneca's revenue was $26.62 billion, an increase of 9.16% compared to the previous year's $24.38 billion. Earnings were $3.14 billion, an increase of 156.23%.
Analyst Forecasts
According to 7 analysts, the average rating for AstraZeneca stock is "Buy." The 12-month stock price forecast is 63.60, which is an increase of 8.89% from the latest price.